Decision Diagnostics Corp. (USOTC:DECN)
Historical Stock Chart
3 Years : From Feb 2014 to Feb 2017
DECN's Pharma Tech Subsidiary Places Significant Order for 50,000 Units of Genstrip 50 for Immediate Delivery to Select U.S. and International Distributors
Genstrip 50 Now Being Manufactured Under Pharma Tech's Rigorous Quality Plan
LOS ANGELES, CA--(Marketwired - Jun 3, 2014) - Decision Diagnostics Corp. (OTCQB: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip™ 50, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that it awaits the pending delivery of 50,000 fifty-count boxes of its Genstrip 50 order. This represents the first order to be manufactured and fulfilled under the governance of the company's new comprehensive quality plan. Additional orders will be processed and shipped as additional volume becomes available.
Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, "Since acquiring the Genstrip intellectual property our focus has been the achievement of an initial manufacturing run, it's thorough testing and its packaging within our redesigned box while under the guidance of our new and comprehensive Quality Plan and System. Last week our Pennsylvania contract manufacturer completed the quality testing of that first manufacturing run of approximately 50,000 fifty-count boxes. Each of those newly manufactured Genstrip boxes adheres to the rigorous standards stipulated in our Procedure Manual and Quality Program. These Strips will shortly begin to fill the growing demand pipeline created by our domestic customers, international distributors and on-line direct patient purchasers.
Robert Jagunich, Chairman of Decision Diagnostics, commented, "The very good news that we would like to share is that few Genstrip customers opted to return or exchange the earlier product version. We strongly believe that this suggests continued product acceptance and patient confidence. We also believe that it portends significant domestic growth and, also, rapid international expansion."
Mr. Berman concluded, "In the coming days we will be issuing an update detailing the plans and the successes of Mark Krakauer, who is spearheading our initiatives in the private label and value added channels. Additional information will also be circulated regarding our International growth; a highlighted area of company focus and concentration. International sales of diabetes supplies are fast outpacing domestic growth by almost 2:1 and have, as a result, consumed a significant increase in the company's attention and resources."
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about the Pharma Tech GenStrip, please visit the company's Web Sites: http://www.decisiondiagnostics.com or http://www.pharmatechdirect.com.
GenStrip™ test strips are a product of Pharma Tech Solutions, Inc., and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan, Inc. a Johnson & Johnson company, manufacturers and distributors of the OneTouch Ultra family of meters and OneTouch Ultra test strips.
Decision Diagnostics Corp.